prt3789
prt3789: developed by 1 company · 2 clinical trials tracked.
prt3789 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could prt3789 → PRLD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Prelude Therapeutics Inc (PRLD) Advanced Solid Tumor | Phase 2 |
Clinical Trials (2)
A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Primary endpoint: Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Primary endpoint: Dose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxel
Frequently asked questions
Who is developing prt3789?
prt3789 is being developed by Prelude Therapeutics Inc.
How many clinical trials involve prt3789?
BioSniper tracks 2 clinical trials involving prt3789.